Search

Your search keyword '"Sabe, Marwa A."' showing total 75 results
Start Over Author "Sabe, Marwa A."
75 results on '"Sabe, Marwa A."'

52. Multiple myeloma and AL amyloid cardiomyopathy

Author

Pankayatselvan, Varayini, primary, Raber, Inbar, additional, Chen, Alvin S., additional, Rathakrishnan, Bharath G., additional, Quintero, Pablo A., additional, Sabe, Marwa A., additional, Freed, Jason A., additional, and Garan, Arthur R., additional

Published
2020
Full Text
View/download PDF

64. Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Author

Sabe, Marwa A., primary, Claggett, Brian, additional, Burdmann, Emmanuel A., additional, Desai, Akshay S., additional, Ivanovich, Peter, additional, Kewalramani, Reshma, additional, Lewis, Eldrin F., additional, McMurray, John J. V., additional, Olson, Kurt A., additional, Parfrey, Patrick, additional, Solomon, Scott D., additional, and Pfeffer, Marc A., additional

Published
2016
Full Text
View/download PDF

71. Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo.

Author

Finney, Marcie R., Fanning, Laura R., Joseph, Matthew E., Goldberg, Jonathan L., Greco, Nicholas J., Bhakta, Shyam, Winter, Daniel G., Forster, Margaret, Scheid, Paul E., Sabe, Marwa, Pompili, Vincent J., and Laughlin, Mary J.

Subjects
CORD blood, BONE marrow cells, BLOOD circulation, EMBRYONIC stem cells, CYTOMETRY, CYTOKINES
Abstract

Background aims. Current clinical trials utilize non-selected bone marrow (BM) mononuclear cells (MNC) to augment vasculo genesis within ischemic vascular beds. Recent reports have identified a diminished number and function of hemat-opoietic stem cells (HSC) from aged and diseased patients. Umbilical cord blood (UCB) provides a potential robust allo-geneic source of HSC for therapeutic vasculogenesis. Methods . MNC and magnetically isolated CD133+ cells were assessed for viability (trypan blue) and surface phenotype (flow cytometry). To test in vivo functionality of the cells, NOD/SCID mice underwent ligation of the right femoral artery followed immediately by cell injection. Blood flow recovery, necrosis, BM engraftment of human cells and histologic capillary density were determined. Cells were tested for potential mechanisms mediating the in vivo effects, including migration, cytokine secretion and angiogenic augmentation (Matrigel assays). Results. Surface expression analysis showed CD31 (PECAM) expression was greatly increased in UCB CD133+ cells compared with BM MNC. At 28 days, perfusion ratios were highest in animals receiving UCB CD133+ cells, while animals receiving BM CD133+ cells and BM MNC demonstrated perfusion ratios statistically higher than in animals treated with cytokine media alone. Animals receiving CD133+ cells showed a statistically higher capillary density, reduced severe digit necrosis and increased engraftment in the BM than animals treated with unselected BM MNC. In vitro studies showed equivalent migration to stromal-derived factor-1 (SDF-1), increased production of tumor necrosis factor alpha (TNF-α) and increased branch points with the co-incubation of CD133+ cells with human umbilical vein endothelial cells (HUVEC) in the Matrigel angiogenesis assay. Conclusions . Taken together, UCB CD133+ cells exhibit robust vasculogenic functionality compared with BM MNC in response to ischemia. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

74. Fulminant cardiac sarcoidosis resembling giant cell myocarditis: a case report.

Author

Jiang GY, Cai Q, Grandin EW, and Sabe MA

Abstract

Background: Severe cardiac sarcoidosis (CS) can share clinical and histopathologic features with giant cell myocarditis (GCM)., Case Summary: A 56-year-old female presented with 1 week of exertional chest pressure and dyspnoea. Echocardiogram demonstrated extensive regional dysfunction with left ventricular ejection fraction (LVEF) 38%. Cardiac catheterization revealed no obstructive coronary artery disease and cardiac index 1.5 L/min/m 2 . Cardiac magnetic resonance imaging (MRI) demonstrated diffuse late gadolinium enhancement. Positron emission tomography with fluorodeoxyglucose (FDG) (FDG-PET) computed tomography showed FDG uptake in the anteroseptal and anterior wall and no extracardiac activity. Endomyocardial biopsy (EMB) demonstrated fragments of endocardial fibrosis with mixed inflammatory infiltrate including histiocytic giant cells, which could be due to CS or GCM. She was initially treated for GCM with high dose steroids, tacrolimus, and mycophenolate mofetil. Repeat EMB was pursued and demonstrated multiple granulomas with sharp demarcation from adjacent uninvolved myocardium consistent with CS. A dual-chamber implantable cardioverter-defibrillator was placed, and immunosuppression was changed to prednisone alone with plan for infliximab., Discussion: This case illustrates a rare presentation of fulminant isolated CS. Endomyocardial biopsy with sufficient tissue was critical to establish a diagnosis and initiate appropriate immunosuppression., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2021
Full Text
View/download PDF

75. Massive retroperitoneal hemorrhage after external shock wave lithotripsy in a patient with a left ventricular assist device.

Author

Gulati G, Kiernan M, and Sabe MA

Abstract

As left ventricular assist devices (LVADs) become more prevalent, it is increasingly likely that patients with LVADs will require non cardiac procedures. Peri-procedural anticoagulation management is challenging in these patients and requires balancing risks of bleeding and pump thrombosis. We present a case of a patient with a HeartWare LVAD who developed a massive retroperitoneal hemorrhage after external shock wave lithotripsy (ESWL) for an obstructing renal calculus and briefly review the literature regarding bleeding complications after ESWL as well as peri-procedural anticoagulation management of patients with LVADs., (© 2019 The Authors. Published by Elsevier Inc.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results